Novavax Plans To Kill COVID-19 in Late 2020 With 100 Million Vaccine Doses

Novavax shares are soaring 37.21% premarket to $106.50 after announcing the company will receive shortly $1.6 billion funding from the federal government to speed up the creation of the COVID-19 vaccine.

As possible COVID-19 second wave approaches, many governments worry about public health for this fall and winter since the virus gets stronger in cold weather. Coming up fast with an effective vaccine against the virus depends not on only biotech corporations but investors and governments aiding with enough funding to save people’s health.

Related:  Myos Rens Technology (MYOS) Nearly Doubles Due To Net Revenues Increase 104%

To finish the late pre-clinical stage of vaccine development and phase 3 trial Novavax needs efficient funds even if they will be started this fall.

NASDAQ: NVAX is rising because of positive news about COVID-19 vaccine development. Its revenue may soar after finishing the complete vaccine but all the revenue costs and operating expenses could never be covered as the public does not want a monopolistic behavior from the healthcare-related companies.

Asan Abdiev

CEO and Editor in Chief. Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life